A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Phase 1/2
170
about 2.9 years
18+
4 sites in MA, MI, TX +1
What this study is about
Researchers are testing the safety and effectiveness of OTP-01, a new medication, in people with advanced solid tumors. The trial will determine the best dose of OTP-01 to see if it can shrink tumors and how well the body processes the drug. Participants will receive OTP-01 through infusions and have blood tests to monitor their health.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take OTP-01
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Phase 1 and Phase 2A: Frequency and Severity of adverse events (AEs) and serious adverse events (SAEs), Phase 2A - Disease Control Rate (DCR), Phase 2A - Duration of Response (DOR), Phase 2A - Objective Response Rate (ORR), Phase 2A - Progression Free Survival (PFS)
Secondary: Phase 1 - Disease Control Rate (DCR), Phase 1 - Duration of Response (DOR), Phase 1 - Objective Response Rate (ORR), Phase 1 - Progression Free Survival (PFS), Phase 1 and Phase 2A - Area under the curve [AUC], Phase 1 and Phase 2A - Clearance [CL], Phase 1 and Phase 2A - Half-life [t1/2], Phase 1 and Phase 2A - Maximum plasma concentration [Cmax]